Quantcast

Latest Stargardt disease Stories

2011-06-16 07:59:00

MARLBOROUGH, Mass., June 16, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the enrollment of the first patients in its two Phase 1/2 clinical trials for Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patients were enrolled at the Jules Stein Eye Institute at the...

2011-05-18 14:21:34

Lab Study Shows an Improved Form of Vitamin A May Help Slowing down the aggregation or "clumping" of vitamin A in the eye may help prevent vision loss caused by macular degeneration, research from Columbia University Medical Center has found. Rather than changing the way the eye processes vitamin A, a team of researchers led by Ilyas Washington, a professor in the department of ophthalmology at Columbia's Harkness Eye Institute, decided to focus on changing the structure of vitamin A itself....

2011-05-05 07:30:00

MARLBOROUGH, Mass., May 5, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that interim chairman and CEO Gary Rabin will be presenting at the World Stem Cells & Regenerative Medicine Congress, May 9-11, in London. Mr. Rabin's presentation, titled "Using ESC-Derived RPE Cells for Dry AMD and Stargardt's Disease," will be given on Monday, May 9. In it, he will provide an update on ACT's...

2011-04-26 07:30:00

MARLBOROUGH, Mass., April 26, 2011 /PRNewswire/ -- Advanced Cell Technology ("ACT"; OTCBB:ACTC), a leader in the regenerative medicine space, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering a keynote lecture at the 3rd International Collaborative Symposium on Stem Cell Research, April 29-30, in Seoul, South Korea. Dr. Lanza's presentation, "The First Human Embryonic Stem Cell Trials," will be delivered on Friday, April 29, and will feature ACT's...

2011-04-20 08:30:00

MARLBOROUGH, Mass., April 20, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has filed a clinical trial application (CTA) with the European Medicines and Healthcare products Regulatory Agency (MHRA) seeking clearance to initiate its Phase 1/2 clinical trial using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular...

2011-03-10 07:30:00

MARLBOROUGH, Mass., March 10, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC), a leader in the field of regenerative medicine, announced today that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has announced a positive opinion of ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells for designation as an orphan medicinal product for the treatment of Stargardt's disease. This...

4f4f197a9b0231ab661663bc7f5117071
2010-11-22 09:05:00

A Massachusetts-based company has been given Food and Drug Administration (FDA) approval to conduct a trial in which embryonic stem cells will be used to treat individuals suffering from an eye condition that can lead to blindness. Advanced Cell Technology (ACT), a biotechnology firm that specializes in regenerative medicine, will use the stem cells to treat individuals suffering from Stargardt's Macular Dystrophy, a degenerative condition that affects the part of the retina where incoming...

2010-02-24 14:36:45

Findings could affect future treatments for macular degeneration, stargardt disease & other forms of retinal disease NEW YORK -- An international research team led by Columbia University Medical Center successfully used mouse embryonic stem cells to replace diseased retinal cells and restore sight in a mouse model of retinitis pigmentosa. This strategy could potentially become a new treatment for retinitis pigmentosa, a leading cause of blindness that affects approximately one in 3,000 to...

2010-02-03 07:10:00

LIVONIA, Mich., Feb. 3 /PRNewswire/ -- To commemorate Low Vision Awareness Month this February, Dr. Sheldon Smith, optometrist at Low Vision of Michigan, P.C., is offering free evaluations to patients diagnosed with retinitis pigmentosa (RP), a leading cause of low vision, in hopes that they might be candidates for a brand-new device designed to enhance or restore sight. Until recently, very little was available to help individuals suffering from RP. However, Dr. Smith, New Jersey...

2009-06-11 15:39:26

Advanced Cell Technology, Inc. (OTC:ACTC.PK) and its collaborators at OHSU reported today the long-term safety and efficacy of human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) produced under manufacturing conditions suitable for human clinical trials. Two important early potential hESC applications are the use of RPE for the treatment of age-related macular degeneration and Stargardt disease, an untreatable form of eye disease that leads to early-onset blindness. The...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related